Fuan Pharmaceutical (Group) Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Lu Wang

Chief executive officer

CN¥776.2k

Total compensation

CEO salary percentage	n/a
CEO tenure	2.9yrs
CEO ownership	n/a
Management average tenure	13.5yrs
Board average tenure	6.4yrs

Recent management updates

Recent updates

CEO

Lu Wang (40 yo)

2.9yrs

Tenure

CN¥776,200

Compensation

Mr. Lu Wang is Vice Chairman and General manager of Fuan Pharmaceutical (Group) Co., Ltd. from December 10, 2021.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Lu Wang	Vice Chairman & GM	no data	CN¥776.20k	no data
Xue Song Yu	Deputy GM	15.2yrs	CN¥608.20k	0.011% CN¥ 653.2k
Tao Huang	Deputy GM & Director	11.9yrs	CN¥698.70k	0.74% CN¥ 45.3m
Xionghui Wu	Deputy General Manager	2.9yrs	CN¥608.00k	0.000080% CN¥ 4.9k
Qin Tang	Secretary of the Board of Directors & Director	15.2yrs	CN¥607.50k	0.024% CN¥ 1.5m
Jing Feng	Deputy General Manager	no data	CN¥608.20k	0.023% CN¥ 1.4m
Rong Chuan Hong	Deputy General Manager	15.2yrs	CN¥615.80k	0.016% CN¥ 956.4k
Yong Ping Sun	Deputy General Manager	4.3yrs	CN¥608.00k	0.025% CN¥ 1.5m

13.5yrs

Average Tenure

53.5yo

Average Age

Experienced Management: 300194's management team is seasoned and experienced (13.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Lu Wang	Vice Chairman & GM	2.9yrs	CN¥776.20k	no data
Xue Song Yu	Deputy GM	15.2yrs	CN¥608.20k	0.011% CN¥ 653.2k
Tao Huang	Deputy GM & Director	11.9yrs	CN¥698.70k	0.74% CN¥ 45.3m
Qin Tang	Secretary of the Board of Directors & Director	15.2yrs	CN¥607.50k	0.024% CN¥ 1.5m
Tianxiang Wang	Chairman	15.2yrs	CN¥919.80k	24% CN¥ 1.5b
Zi Wei Guo	Supervisor	6.4yrs	CN¥197.50k	no data
Wei Wang	Director	6.4yrs	CN¥631.50k	no data
Wen Shuo Xiong	Independent Director	5.9yrs	CN¥60.00k	no data
Shu Zhu	Independent Director	5.9yrs	CN¥60.00k	no data
Geng Chen	Independent Director	2.9yrs	CN¥60.00k	no data
Yong Yang	Chairman of the Supervisory Board	2.3yrs	no data	no data

6.4yrs

Average Tenure

54yo

Average Age

Experienced Board: 300194's board of directors are considered experienced (6.4 years average tenure).

Fuan Pharmaceutical (Group) Management

Management criteria checks 4/4

Key information

Recent management updates

Fuan Pharmaceutical (Group) Co., Ltd., Annual General Meeting, May 24, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.07 in 3Q 2023)

Investor sentiment improves as stock rises 27%

Fuan Pharmaceutical (Group) Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Second quarter 2024 earnings released: EPS: CN¥0.08 (vs CN¥0.07 in 2Q 2023)

Fuan Pharmaceutical (Group) Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Fuan Pharmaceutical (Group) Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 04 June 2024

Fuan Pharmaceutical (Group) Co., Ltd. Proposes Final Cash Dividend for 2023

Fuan Pharmaceutical (Group) Co., Ltd., Annual General Meeting, May 24, 2024

First quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.07 in 1Q 2023)

Fuan Pharmaceutical (Group) Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Investor sentiment deteriorates as stock falls 17%

Fuan Pharmaceutical (Group) Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024

Third quarter 2023 earnings released: EPS: CN¥0.07 (vs CN¥0.04 in 3Q 2022)

Investor sentiment improves as stock rises 19%

Second quarter 2023 earnings released: EPS: CN¥0.07 (vs CN¥0.04 in 2Q 2022)

Fuan Pharmaceutical (Group) Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on 12 May 2023

First quarter 2023 earnings released: EPS: CN¥0.07 (vs CN¥0.03 in 1Q 2022)

Now 21% undervalued

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.06 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.04 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.03 (vs CN¥0.05 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.25 loss per share (vs CN¥0.18 profit in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.05 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.04 (vs CN¥0.05 in 2Q 2020)

Fuan Pharmaceutical (Group) Co., Ltd. Announces Implementation of Profit Distribution Plan for A Shares for the Year 2020, Payable on 14 May 2021

First quarter 2021 earnings released: EPS CN¥0.05 (vs CN¥0.06 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.18 (vs CN¥0.25 in FY 2019)

Fuan Pharmaceutical (Group) Co., Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: CN¥4.18

New 90-day low: CN¥4.74

New 90-day low: CN¥5.42

New 90-day high - CN¥6.57

Fuan Pharmaceutical (Group) Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

New 90-day high - CN¥6.27

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age